Amgen (AMGN) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to -$9.4 billion.
- Amgen's Enterprise Value fell 481.63% to -$9.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.4 billion, marking a year-over-year decrease of 481.63%. This contributed to the annual value of -$12.0 billion for FY2024, which is 940.24% down from last year.
- Amgen's Enterprise Value amounted to -$9.4 billion in Q3 2025, which was down 481.63% from -$8.0 billion recorded in Q2 2025.
- Amgen's Enterprise Value's 5-year high stood at -$6.5 billion during Q1 2022, with a 5-year trough of -$34.7 billion in Q3 2023.
- Its 5-year average for Enterprise Value is -$13.3 billion, with a median of -$9.4 billion in 2025.
- Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 38290.04% in 2023, then skyrocketed by 7406.23% in 2024.
- Amgen's Enterprise Value (Quarter) stood at -$8.0 billion in 2021, then dropped by 15.78% to -$9.3 billion in 2022, then decreased by 17.61% to -$10.9 billion in 2023, then fell by 9.4% to -$12.0 billion in 2024, then rose by 21.11% to -$9.4 billion in 2025.
- Its Enterprise Value was -$9.4 billion in Q3 2025, compared to -$8.0 billion in Q2 2025 and -$8.8 billion in Q1 2025.